Carboplatin, Nab-paclitaxel, and Vorinostat Combination

The combination of carboplatin, nab-paclitaxel, and vorinostat is an investigational treatment regimen that has been studied in clinical trials for various cancer types. This combination brings together conventional chemotherapy agents (carboplatin and nab-paclitaxel) with a histone deacetylase inhibitor (vorinostat). ## Composition and Mechanism This combination therapy consists of three distinct drugs: 1. **Carboplatin**: A platinum-based chemotherapy drug that works by binding to DNA and interfering with cell division, ultimately leading to cancer cell death. 2. **Nab-paclitaxel** (albumin-bound paclitaxel): A formulation of paclitaxel that uses albumin nanoparticles to deliver the drug more effectively to tumor cells. It works by stabilizing microtubules, preventing cell division. 3. **Vorinostat**: A histone deacetylase (HDAC) inhibitor that affects gene expression by preventing the removal of acetyl groups from histones, potentially making cancer cells more sensitive to chemotherapy drugs. The rationale behind this combination is that vorinostat may enhance the efficacy of carboplatin and nab-paclitaxel by making tumor cells more sensitive to these chemotherapy agents[2]. Vorinostat exerts anticancer effects through both histone and non-histone-mediated mechanisms[1][3]. ## Clinical Development This combination has been studied in clinical trials for several cancer types: - **Breast Cancer**: A randomized phase II trial (NCT00616967) investigated carboplatin and nab-paclitaxel with or without vorinostat in treating women with newly diagnosed operable breast cancer[2][6][9][10]. The purpose was to determine if adding vorinostat to the chemotherapy regimen before surgery could make tumors smaller and reduce the amount of normal tissue that needs to be removed. - **Non-Small Cell Lung Cancer (NSCLC)**: While not specifically with nab-paclitaxel, a related combination of carboplatin, standard paclitaxel, and vorinostat showed promising results in a phase II randomized, double-blinded, placebo-controlled study for advanced NSCLC. The confirmed response rate was 34% with vorinostat versus 12.5% with placebo, with trends toward improved progression-free survival and overall survival[1][3]. - **Ovarian Cancer**: A phase II study evaluated vorinostat with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer, showing an objective response rate of 62.2% and median overall survival of 40.6 months[5]. ## Administration In the breast cancer trial, the treatment regimen involved: - Carboplatin administered intravenously - Nab-paclitaxel administered intravenously - Vorinostat administered orally on days 1-3 of each treatment cycle[2] ## Safety Profile When vorinostat is combined with carboplatin and paclitaxel, common adverse events include: - Hematological toxicities: thrombocytopenia, anemia, neutropenia - Gastrointestinal effects: nausea, emesis, anorexia, diarrhea - Other: fatigue, dehydration, hyponatremia, sensory neuropathy, myalgia, stomatitis[1][3][5] In the NSCLC study, grade 4 platelet toxicity was more common with vorinostat (18% vs. 3%)[1][3]. This combination represents an investigational approach that aims to improve outcomes in cancer treatment by combining conventional chemotherapy with epigenetic modulation through HDAC inhibition.